Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26469046 | 1.00 | CYP11B2 (0.43) | CYP11B2CYP11B1CYP17A1CYP3A4NQO2 | |
| SCHEMBL30296309 | 0.81 | CYP11B2 (0.42) | CYP11B2CYP11B1TDO2 | |
| SCHEMBL31026729 | 0.80 | CYP11B1 (0.46) | CYP11B2CYP11B1CYP17A1CYP3A4BACE1 | |
| SCHEMBL30296372 | 0.80 | NQO2 (0.48) | CYP11B2CYP11B1CYP17A1CYP3A4NQO2 | |
| SCHEMBL26091993 | 0.80 | NQO2 (0.48) | CYP11B2CYP11B1CYP17A1CYP3A4NQO2 | |
| SCHEMBL30296246 | 0.77 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP17A1TDO2 | |
| SCHEMBL30296678 | 0.77 | FEN1 (0.36) | GAA | |
| SCHEMBL26923363 | 0.77 | PARP10 (0.38) | CYP11B2CYP11B1CYP17A1CYP3A4CYP19A1 | |
| SCHEMBL26922914 | 0.77 | CYP11B2 (0.44) | CYP11B2CYP11B1CYP17A1CYP3A4NQO2 | |
| SCHEMBL26459206 | 0.77 | FEN1 (0.36) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | CYP11B2 328/4885CYP11B1 309/4885CYP17A1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.